Core Insights - Zimmer Biomet exceeded Wall Street expectations for fourth-quarter profit and revenue, driven by consistent demand for its orthopedic devices [1] Company Performance - The company reported a strong performance in the fourth quarter, indicating robust market conditions for its products [1] Industry Demand - There is steady demand for orthopedic devices, which has positively impacted Zimmer Biomet's financial results [1]

Financial Performance - Fourth quarter net sales reached $2.244 billion, a 10.9% increase year-over-year, with a 5.4% increase on an organic constant currency basis [2]. - Full-year net sales totaled $8.232 billion, reflecting a 7.2% increase compared to the previous year, with a 3.9% increase on an organic constant currency basis [3]. - Fourth quarter diluted earnings per share were $0.70, a decrease of 41.7%, while adjusted diluted earnings per share increased by 4.8% to $2.42 [4]. - Full-year net earnings were $705.1 million, with adjusted net earnings of $1.629 billion, marking a 2.5% increase in adjusted diluted earnings per share to $8.20 [3]. - Operating profit for the year 2025 was $1,098.1 million, down from $1,285.7 million in 2024, indicating a decrease of about 14.6% [40]. - Net earnings for 2025 were $705.1 million, compared to $903.8 million in 2024, reflecting a decline of approximately 22% [40]. - Basic earnings per share for 2025 were $3.56, down from $4.45 in 2024, a decrease of about 20% [40]. - Reported net earnings for the year ended December 31, 2025, were $705.1 million, with diluted earnings per share at $3.55 [52]. - Total revenue for the year ended December 31, 2025, was $3,257.2 million, reflecting a significant increase compared to the previous year [52]. Cash Flow and Investments - The company generated $1.697 billion in operating cash flow and $1.172 billion in free cash flow for the year [4]. - Net cash provided by operating activities increased to $1,697.1 million in 2025, compared to $1,499.4 million in 2024, representing a growth of about 13.3% [44]. - The company reported a net cash used in investing activities of $1,975.7 million in 2025, compared to $888.1 million in 2024, indicating a substantial increase in investment activities [44]. - Free cash flow for the three months ended December 31, 2025, was $368.3 million, down from $402.8 million in the same period of 2024 [58]. Stock and Debt Management - A new stock repurchase authorization of up to $1.5 billion was approved, effective February 9, 2026 [5]. - Zimmer Biomet completed $250 million in share repurchases during the fourth quarter of fiscal 2025 [8]. - The company’s long-term debt increased to $6,932.0 million in 2025 from $5,341.6 million in 2024, reflecting a rise of approximately 30% [42]. - Total debt increased to $7,519.1 million in December 2025 from $6,204.6 million in December 2024, reflecting a significant rise [63]. - Net debt rose to $6,927.2 million in December 2025, up from $5,679.1 million in December 2024, indicating increased leverage [63]. Research and Development - Research and development expenses increased to $458.5 million in 2025 from $437.4 million in 2024, showing a growth of approximately 4.8% [40]. Future Projections - Projected revenue change for 2026 is estimated at 2.5% - 4.5%, with adjusted diluted EPS guidance of $8.30 - $8.45 [17]. - The company anticipates organic constant currency revenue change for the year ending December 31, 2026, but specific figures were not provided due to the nature of forward-looking statements [32]. - The company is transitioning to a predominantly direct and specialized sales organization in the U.S., which may temper 2026 sales guidance but is expected to drive long-term growth [6]. Operational Highlights - The company received FDA clearance for the ROSA® Knee with OptimiZe™, enhancing its robotic knee system [8]. - The S.E.T. product category saw a significant increase of 15.2% in net sales for the year, with a constant currency growth of 14.6% [46]. - In the United States, net sales grew by 7.3%, while international sales increased by 7.0% for the year ended December 31, 2025 [46]. Asset Management - Total assets as of December 31, 2025, were $23,091.7 million, up from $21,365.3 million in 2024, an increase of about 8.1% [42]. - Cash and cash equivalents rose to $591.9 million in 2025, compared to $525.5 million in 2024, representing an increase of approximately 12.6% [42]. - Cash and cash equivalents at the end of the period rose to $591.9 million, up from $525.5 million at the beginning of the year [44].

Core Viewpoint - Zimmer Biomet Holdings, Inc. (ZBH) is set to report its fourth-quarter 2025 results on February 10, with expectations of revenue growth and earnings per share (EPS) increase compared to the previous year [1][9]. Group 1: Financial Estimates - The Zacks Consensus Estimate for ZBH's revenues is $2.20 billion, reflecting an 8.9% increase from the same quarter last year [2]. - The consensus estimate for earnings is $2.38 per share, indicating a 3% rise from the year-ago figure [2]. - The bottom-line estimate has remained unchanged over the past 30 days [2]. Group 2: Business Segment Performance - The Hips business is expected to grow due to the company's comprehensive solutions, including the new Z1 triple-taper hip system and the automated HAMMR surgical impactor [3][4]. - The total Hips business is projected to report a 10.5% year-over-year growth [5]. - The Knees business is likely to benefit from the increasing adoption of the Persona OsseoTi cementless total knee system, with an expected 7.5% year-over-year growth [6]. - The S.E.T business is anticipated to continue its growth trend, with expectations of mid-single-digit growth for the seventh consecutive quarter [7]. - New product launches in the foot and ankle trauma portfolio, such as the Gorilla Pilon Fusion Plating system, may positively impact fourth-quarter performance [8]. Group 3: Recent Developments - Zimmer Biomet received PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System, which may enhance top-line performance [5]. - The acquisition of Paragon 28, Inc. and the CE Mark certification for the RibFix Advantage Fixation System are expected to contribute positively to the company's performance [10]. - The company completed the acquisition of Monogram Technologies Inc., an AI-driven orthopedic robotics firm, which may also have a favorable impact on fourth-quarter results [12]. Group 4: Growth Projections - The Technology & Data, Bone Cement, and Surgical business is estimated to report a 6.5% year-over-year growth for the quarter [13]. - The total S.E.T. business is projected to achieve a 13% year-over-year growth [10].

Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH) due to concerns over the company's "high confidence" assurances regarding its 2025 revenue targets following a significant stock decline and reduced revenue guidance [1][4]. Group 1: Investigation Focus - The investigation aims to determine if Zimmer Biomet's senior management misled investors about the stability of its international business, particularly after the company reported distributor order cancellations in emerging markets and a revenue miss in Latin America [2][4]. - The investigation is centered on whether Zimmer Biomet violated federal securities laws by providing overly optimistic guidance while concealing operational disruptions [4]. Group 2: Management Statements and Market Reaction - On August 7, 2025, during the Q2 earnings call, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, which contributed to a 7% increase in share price that day [7]. - Following the November 5, 2025 earnings report, which revealed a lower-than-expected organic revenue growth of 5% and a revised forecast of 4%, the stock price fell by 15% as the CEO acknowledged the need for more measured external commentary [7]. Group 3: Operational Challenges - The November report indicated that emerging markets posed a headwind to growth, with significant distributor order cancellations primarily in the Middle East and Eastern Europe, and a substantial revenue miss in Latin America [7]. - The company announced leadership and governance changes in some international businesses to address the challenges faced throughout 2025 [7].

Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. due to concerns over the company's previously stated "high confidence" in its 2025 revenue targets following significant operational disruptions and revenue misses in emerging markets [1][4]. Group 1: Investigation Details - The investigation focuses on whether Zimmer Biomet's senior management misled investors about the stability of its international business, particularly after assurances of strong growth in August 2025 [2][4]. - Following the company's November 5, 2025 disclosure of distributor order cancellations in emerging markets and a revenue miss in Latin America, Zimmer Biomet's stock fell by 15%, significantly impacting its market value [2][6]. Group 2: Management Statements and Market Reaction - In August 2025, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, which contributed to a 7% increase in share price on that day [6]. - The November 5 earnings call revealed that the actual year-over-year organic revenue growth was only 5%, leading to a reduction in the growth forecast to 4% and acknowledgment of emerging markets as a headwind [6]. Group 3: Leadership Changes and Future Guidance - Zimmer Biomet announced leadership and governance changes in response to the challenges faced in international markets throughout 2025 [6]. - CEO Ivan Tornos stated the need for more measured external commentary following the scrutiny from analysts, indicating a shift in the company's communication strategy [6].

Core Insights - Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has presented cautious expectations for 2026, indicating significant internal changes are planned [2] - The company revised its 2025 organic revenue growth forecast down to 4.00% from 4.50% due to weaker demand in Latin America and emerging European markets, although overall revenue growth estimates remained stable due to favorable currency impacts [2] - Management cited last-minute cancellations of distributor orders from the Middle East and Eastern Europe as a key factor affecting performance [2] Company Ratings and Price Targets - Bernstein raised its price target for Zimmer Biomet Holdings from $97.00 to $99.00 while maintaining a 'Market Perform' rating, noting improving clarity in macro and policy uncertainties for U.S. healthcare stocks [2] - JPMorgan maintained a 'Neutral' rating on the company with a $100 price target, viewing 2026 as a pivotal year with growth opportunities while fundamentals remain strong [2] Business Focus - Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and marketing orthopedic, spine, dental, and surgical products globally [2]

Core Viewpoint - Zimmer Biomet Holdings, Inc. will host its fourth quarter earnings conference call on February 10, 2026, at 8:30 a.m. ET, with a news release detailing the quarterly results available at 6:30 a.m. ET on the same day [1]. Group 1: Earnings Call Details - The earnings conference call will be accessible via a live audio webcast on Zimmer Biomet's Investor Relations website, with a replay available after the call [2]. - U.S. and Canada participants can join the call by dialing (800) 330-6710, while international callers should use +1 (213) 279-1505, both requiring conference ID 7090861 [2]. Group 2: Company Overview - Zimmer Biomet is recognized as a global leader in medical technology, offering a comprehensive portfolio aimed at enhancing mobility and health [3]. - The company focuses on transforming patient experiences through innovative products and integrated digital and robotic technologies that utilize data analytics and artificial intelligence [3]. - With over 90 years of experience, Zimmer Biomet is committed to delivering high-quality solutions to patients and healthcare providers, reflecting a culture of evolution and innovation [4].

Group 1 - The presentation is led by Ivan Tornos, who is the President, CEO, and Chairman of the Board of Zimmer Biomet [1] - The company aims to summarize its presentation quickly to accommodate the busy schedule of the audience, which includes numerous presentations over the next few days [2] - Zimmer Biomet expresses satisfaction with the progress made over the last five years, indicating a positive outlook for the company in 2026 [3]

Summary of Zimmer Biomet FY Conference Call (January 13, 2026) Company Overview - **Company**: Zimmer Biomet (NYSE: ZBH) - **Industry**: Medical Technology (MedTech), specifically Orthopedics Key Points and Arguments Company Transformation and Growth - Zimmer Biomet has undergone significant transformation over the past five years, shifting from a product-focused to a solutions-oriented approach, with an emphasis on cultural change [4][5] - The company reported a Compound Annual Growth Rate (CAGR) of 6.5% over the last five years, with revenue growth of 10% in 2021, 6.5% in 2022, and 7.5% in 2023 [5][6] - Adjusted earnings per share (EPS) for 2023 was $9.50, with a leverage of 200 basis points [5] U.S. Market Focus - The U.S. market accounts for 63% of Zimmer Biomet's revenue and over 51% of its debt [7] - The company aims to accelerate the transformation of its sales model in the U.S. to improve accountability and ownership [6][7] - A significant change in the U.S. sales model is planned, with a focus on specialization and direct sales [22] Innovation and Product Development - The company has shifted from launching eight products in 2018 to over 50 new products in the last three years, with 22 launched in 2025 alone [10][11] - Key innovations include the introduction of the first iodine-coated device aimed at preventing infections, set to launch in Japan in late 2025 [17][18] - The company is focusing on customer-centric innovation, addressing issues such as infection, efficiency, and patient outcomes [20][31] Market Dynamics - The orthopedic market is projected to grow at a rate of 4% to 4.25%, with Zimmer Biomet's performance tied to maintaining growth above this benchmark [13] - The company has seen consistent price positivity over the last seven quarters, indicating a favorable pricing environment [42] Financial Outlook - The company expects free cash flow to grow by 70% over the next five to six years, with 2026 anticipated to see free cash flow growth outpacing EPS growth [27][56] - Guidance for 2026 is tempered, aligning with the level of transformation expected, with projected organic growth of 3.5% to 4% [35][36] Strategic Investments - Zimmer Biomet has made three acquisitions in the past 14 months, including OrthoGrid and Paragon 28, to enhance its product offerings and market position [27][28] - The company plans to significantly increase its workforce dedicated to robotic solutions and ASCs (Ambulatory Surgery Centers) [24][25] Challenges and Execution - The company acknowledges the need for improved execution to ensure steady growth, addressing past inconsistencies in quarterly performance [20][21] - The transition to a specialized sales force is expected to create short-term disruptions but aims for mid- to long-term growth acceleration [46] Future Vision - By 2030, Zimmer Biomet aims to innovate beyond traditional implants, focusing on cartilage repair and leveraging data for predictive analytics in orthopedic care [32][33][34] Additional Important Insights - The company has improved employee engagement, making it to Forbes' World's Best Employers list for the first time [11] - Zimmer Biomet is committed to building a best-in-class company, focusing on operational excellence, innovation, and a strong company culture [30][34] This summary encapsulates the key points discussed during the conference call, highlighting Zimmer Biomet's strategic direction, market dynamics, and future aspirations in the orthopedic industry.

Core Insights - Dentsply Sirona has appointed Mark R. Bezjak as Group Vice President for the Americas Regional Commercial Organization, effective January 28, 2026, to enhance commercial execution and accelerate growth across the Americas [1][2]. Group 1: Appointment and Role - The appointment of Mark R. Bezjak is aimed at strengthening Dentsply Sirona's commercial execution and deepening customer relationships [2]. - Mr. Bezjak has over 20 years of experience in the medical device industry, having previously served as President of the Americas division at Zimmer Biomet [2][4]. - His leadership experience includes driving commercial transformations and achieving consistent revenue and operating income growth [2][4]. Group 2: Leadership Perspective - Aldo Denti, EVP and Chief Commercial Officer, emphasized that Bezjak's appointment is crucial for executing the company's growth strategy and enhancing customer focus [3]. - Bezjak's background in Orthopedics aligns with Dentsply Sirona's goals of improving customer engagement and field execution [3]. Group 3: Background of Mark R. Bezjak - Mr. Bezjak has held multiple senior leadership roles at Zimmer Biomet, focusing on commercial transformation and financial management [4]. - He has a Bachelor of Science in Marketing from Virginia Tech and an MBA from the University of Richmond [4]. Group 4: Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, with a history of over a century in the dental industry [5]. - The company offers a comprehensive range of dental and oral health products, aiming to advance patient care and improve dental services [5].